TY - JOUR
T1 - Primary cardiac sarcomas
T2 - Treatment strategies
AU - Chan, Edward Y.
AU - Ali, Areeba
AU - Zubair, M. Mujeeb
AU - Nguyen, Duc T.
AU - Ibarra-Cortez, Sergio H.
AU - Graviss, Edward A.
AU - Shapira, Oz M.
AU - Ravi, Vinod
AU - MacGillivray, Thomas E.
AU - Reardon, Michael J.
N1 - Publisher Copyright:
© 2022 The American Association for Thoracic Surgery
PY - 2022
Y1 - 2022
N2 - Objective: Our multidisciplinary cardiac tumor team now has an experience of operating on 122 cases of primary cardiac sarcoma over a 23-year period. The purpose of this study is to present our short- and long-term outcomes for cardiac sarcoma. Methods: We performed a retrospective review of a prospectively collected Institutional Review Board–approved cardiac tumor database for cardiac sarcoma. Patient characteristics, surgical factors, and patient outcomes were analyzed. Perioperative data were collected from direct patient communication and all available medical records. The primary end point was all-cause mortality at 1, 3, and 5 years from the time of our surgery and 1, 3, and 5 years from the initial diagnosis. The secondary end point was all-cause mortality between the first and second halves of the study. Results: From October 1998 to April 2021, we operated on 122 patients with a primary cardiac sarcoma. The mean age was 45.3 years old, and 52.5% were male. Tumors were most frequently found in the left atrium (40.2%) and right atrium (32.0%). The most common type of tumor histologically was an angiosarcoma (38.5%), followed by high-grade sarcoma (14.8%). Survival from initial diagnosis at 1, 3, and 5 years was 88.4%, 43.15%, and 27.8%, respectively. Survival from surgery at our institution at 1 and 3 years was 57.1% and 24.5%, respectively. When comparing outcomes from different time periods, we found no significant difference in survival between the previous era (1998-2011) and the current era (2011-2021). Conclusions: Management of these complex patients can show reasonable outcomes in centers with a multidisciplinary cardiac tumor team. Mortality has not improved with time and is likely related to the systemic nature of this disease.
AB - Objective: Our multidisciplinary cardiac tumor team now has an experience of operating on 122 cases of primary cardiac sarcoma over a 23-year period. The purpose of this study is to present our short- and long-term outcomes for cardiac sarcoma. Methods: We performed a retrospective review of a prospectively collected Institutional Review Board–approved cardiac tumor database for cardiac sarcoma. Patient characteristics, surgical factors, and patient outcomes were analyzed. Perioperative data were collected from direct patient communication and all available medical records. The primary end point was all-cause mortality at 1, 3, and 5 years from the time of our surgery and 1, 3, and 5 years from the initial diagnosis. The secondary end point was all-cause mortality between the first and second halves of the study. Results: From October 1998 to April 2021, we operated on 122 patients with a primary cardiac sarcoma. The mean age was 45.3 years old, and 52.5% were male. Tumors were most frequently found in the left atrium (40.2%) and right atrium (32.0%). The most common type of tumor histologically was an angiosarcoma (38.5%), followed by high-grade sarcoma (14.8%). Survival from initial diagnosis at 1, 3, and 5 years was 88.4%, 43.15%, and 27.8%, respectively. Survival from surgery at our institution at 1 and 3 years was 57.1% and 24.5%, respectively. When comparing outcomes from different time periods, we found no significant difference in survival between the previous era (1998-2011) and the current era (2011-2021). Conclusions: Management of these complex patients can show reasonable outcomes in centers with a multidisciplinary cardiac tumor team. Mortality has not improved with time and is likely related to the systemic nature of this disease.
KW - autotransplant
KW - sarcoma
KW - tumor
UR - http://www.scopus.com/inward/record.url?scp=85125451163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125451163&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2021.10.070
DO - 10.1016/j.jtcvs.2021.10.070
M3 - Article
C2 - 35219517
AN - SCOPUS:85125451163
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
SN - 0022-5223
ER -